DS
RVNC

DRW Securities’s Revance Therapeutics, Inc. RVNC Stock Holding History

DRW Securities’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-34,000
Closed -$1.09M – 112
2015
Q2 		$1.09M Buy
+34,000
New +$874K 0.12% 33

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DRW Securities's RVNC Position: Q3 2015 in Review

DRW Securities sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2015, closing a stake of 34,000 shares — an estimated $1.09M sold.

DRW Securities first reported a position in RVNC in Q2 2015 and held it in 1 quarter. The position peaked at $1.09M in Q2 2015. 79 funds tracked by Wall St. Rank hold RVNC as of Q3 2015.

  • DRW Securities reported no remaining Revance Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • DRW Securities sold 34,000 Revance Therapeutics, Inc. shares in Q3 2015, an estimated $1.09M.
  • DRW Securities first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • DRW Securities's Revance Therapeutics, Inc. position peaked at $1.09M in Q2 2015.
  • 79 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2015.

Based on DRW Securities's 13F filing for Q3 2015, filed 16 Nov 2015.